About us
What we do
Our strategy
Market opportunity
Our team
Our History
Origins – Institute of Cancer Therapeutics (ICT) Bradford
Pipeline
Our products
For patients
Partnering
Our partnerships
Investors
Overview
Why invest?
IPO materials
Regulatory news
Results, Reports and Presentations
Research Notes
Email alerts
Share price and tools
Financial calendar
Shareholder information
Investor and Advisor contacts
AQSE Growth Market Rule 4.14
Corporate Governance
Company Contact Details
News & media
News
Press Coverage
Scientific Publications
Contact Us
Sustainability
Share price
INC 05.15 GBp
About us
What we do
Our strategy
Market opportunity
Our team
Board of Directors
Senior Management
Advisors and Founders
Our History
Origins – Institute of Cancer Therapeutics (ICT) Bradford
Pipeline
Our products
For patients
Partnering
Our partnerships
Investors
Overview
Why invest?
IPO materials
Regulatory news
Results, Reports and Presentations
Research Notes
Email alerts
Share price and tools
Share price chart
Detailed share price
Financial calendar
Shareholder information
Shareholder Information
AGM
GM
Analyst coverage
Investor and Advisor contacts
AQSE Growth Market Rule 4.14
Corporate Governance
Corporate Governance Report
QCA Corporate Governance Principles
Company Contact Details
News & media
News
Press Coverage
Scientific Publications
Contact Us
Sustainability
News
Home
News & media
News
Latest from Incanthera
News
2024
2023
2022
Archive
September 28th, 2020
Successful Results of Sensitisation Study
View
September 22nd, 2020
Incanthera delighted as Sol outshines rivals in new study
View
September 22nd, 2020
Successful Results of Permeation Study
View
July 28th, 2020
New Patent Filing for Sol Skin Cancer Technology
View
July 28th, 2020
Incanthera submits new patent application for cancer preventing sun cream
View
July 15th, 2020
Result of Annual General Meeting
View
Prev
4
5
6
Next